Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Asthma research in Europe: a transformative agenda for innovation and competitiveness

Nikolaos G. Papadopoulos, Aggeliki Androutsopoulou, Cezmi Akdis, Sven-Erik Dahlén, Ratko Djukanovic, Jessica Edwards, Luis Garcia-Marcos, Sebastian L. Johnston, Maciek Kupczyk, Thomas R. Martin, David Myles, Susanna Palkonen, Pippa Powell, John Riley, Samantha Walker
European Respiratory Journal 2017 49: 1602294; DOI: 10.1183/13993003.02294-2016
Nikolaos G. Papadopoulos
1National Kapodistrian University of Athens, Athens, Greece
2University of Manchester, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ngpallergy@gmail.com
Aggeliki Androutsopoulou
1National Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aggeliki Androutsopoulou
Cezmi Akdis
3Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich Faculty of Medicine, Davos, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven-Erik Dahlén
4IMM Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ratko Djukanovic
5NIHR Southampton Respiratory Biomedical Research Unit, University of Southampton, Southampton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Edwards
6Asthma UK, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Garcia-Marcos
7Paediatric Pulmonology and Allergy, “Virgen de la Arrixaca” University Children's Hospital, University of Murcia, Murcia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian L. Johnston
8National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maciek Kupczyk
9Medical University of Łódź, Łódź, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas R. Martin
10Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Myles
11GlaxoSmithKline, Stevenage, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna Palkonen
12European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pippa Powell
13European Lung Foundation (ELF), Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Riley
11GlaxoSmithKline, Stevenage, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Walker
6Asthma UK, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Asthma research in Europe: a transformative agenda for innovation and competitiveness http://ow.ly/YssR30aNG9h

Asthma is highly prevalent, often starting in infancy and persisting throughout life, and is associated with high morbidity and burden. It is a major global health challenge with growing impact, affecting more than 300 million people worldwide and at least 10% of all Europeans [1]. Furthermore, it is the most prevalent long-term condition in children [2]. Approximately 5–10% of asthma cases are so severe that current treatments do not work, and over five million people in the European Union (EU) fall into this category.

People with asthma live at risk of life-threatening asthma attacks, leading to at least 500 000 hospitalisations worldwide each year [3]. A European study estimated that unscheduled care and rescue medication accounted for 47% of the total cost-per-patient in infants, 45% in children and 56% in adults [4]. This results in high socio-economic impact, estimated at more than €70 billion annually [1]. This includes the costs of direct primary and hospital healthcare (estimated to be close to €20 billion per annum), costs due to lost productivity (€14 billion) [1], and the monetised value of disability-adjusted life-years (DALYs) lost (over €38 billion) [1]. Close to 1 million DALYs are lost due to asthma in Europe every year [5].

Despite the fact that the direct and indirect costs of asthma are substantial and continue to rise, asthma remains under-prioritised in the EU research agenda. Only 0.5% of the Seventh Framework Programme (FP7) health research budget was devoted to asthma and chronic obstructive pulmonary disease (COPD) (€30 million) [5]. In comparison, some 5.4 times this amount (over €163 million) was spent on cardiovascular conditions and some 20.6 times (over €618 million) on brain research.

Asthma, with its high global prevalence and an associated multi-billion global market for treatments, plus its historical underfunding and the demand for new treatments and diagnostics, represents an enormous opportunity to drive substantial economic growth. This paper sets out how the EU may capitalise on this via investment in research with high commercial potential that can radically improve the EUs research agenda and public health.

Europe at the forefront of a medical research revolution: an opportunity for change

Demonstrable success in European asthma research has been achieved over the past two decades but there is still much more to do. Research priorities have been identified and opportunities lie ahead to fulfil them [6]. The digital revolution can become an aid for the self-management of long-term conditions. Advances in genomics and disease stratification can provide a radical approach to current challenges, offering life-changing benefits for people who do not respond to existing treatments. So-called “big-data” can be harnessed to assist healthcare professionals and policy makers in making efficient judgements about how and when to treat people and improve healthcare systems. Electronic and mobile systems (e-health and m-health) can now provide personalised medicine, offering new devices and programmes with more penetration into younger age groups.

The EUs “Europe 2020” strategy for jobs and growth sets out to address societal challenges through research and innovation whilst recognising the role that research has in promoting economic competitiveness. The “Innovation Union” initiative recognises the need to promote research in areas of high commercial potential, whilst bridging the gap between research breakthroughs and the market. Both express the need for a more collaborative research framework, linking public and private stakeholders around common goals, including small and medium enterprises (SMEs).

A key EU initiative in collaboration with the European pharmaceutical industry is the Innovative Medicines Initiative (IMI), which is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly where there is an unmet medical or social need. It does this by facilitating collaboration between universities, the pharmaceutical and other industries, SMEs, patient organisations, and regulators.

One major achievement of the IMI is the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) project (2009–2015) [7]. U-BIOPRED received much praise from the IMI as one of its most effective collaborative efforts, since it delivered a significant enhancement in the understanding of asthma and an impact on decision making within the pharmaceutical industry (which actively uses U-BIOPRED data).

The EU has put forward European Innovation Partnerships (EIPs) as initiatives to address societal challenges though private and public involvement in innovation. These have set the basis for further improvement and realisation of the full potential of public–private partnerships.

Asthma: an unmet need and an economic opportunity

Asthma is arguably the best example of the opportunities associated with personalised-medicine, bioinformatics and e-health. Advances in personalised medicine will depend on access to large patient cohorts and core phenotype information [8]. Asthma is variable and much of the difficulty in understanding its mechanisms and developing new therapies comes from the multiplicity of phenotypes. The treatment pipeline for severe asthma is now exciting as it takes significant advantage of stratification, thus having the potential for breakthroughs in personalised medicine.

Asthma has one of the best cases for effective self-management and improved outcomes, as approximately 80% of people with asthma could effectively self-manage, primarily through improved medication adherence. The size of the problem and it socioeconomic impact, the potential for improvement and eventual solution, the wide implications in the economic process, and the wide interactions at various levels of the innovation chain should establish asthma as a European priority to be resolved through innovation.

The European Asthma Research and Innovation Partnership: a transformative agenda for research and innovation

The European Asthma Research and Innovation Partnership (EARIP) is an EU-funded initiative designed to inform EU research and innovation priorities by bringing together key stakeholders across a wide range of disciplines. Partners have worked over the past 3 years to develop a coordinated agenda for asthma research and innovation that will position Europe as the front-runner to address this major health and societal challenge [9]. EARIP proposes that research should focus on areas with high potential for commercial breakthroughs, such as diagnostics and e-health, and where stakeholders are linked around a common goal. Platforms streamlining communication and closer links between innovators, policy makers and regulators, crucially involving the EU member states, will speed up market uptake.

A stakeholder mapping exercise initiated through EARIP has revealed the width and potential of the area and forms a basis for reference and for expansion into a prospective registry (figure 1). EARIP firmly believes that patients and the public should be at the core of any initiative, to ensure that policy makers, healthcare professionals and industry understand their perspective and design research and innovation around their needs. The European Federation for Allergy and Airways Diseases Patients' Associations (EFA) is driving this by engaging patients and facilitating their communication with various bodies. This is being supported by the European Lung Foundation (ELF) which coordinated an asthma research roadmap as part of EARIP [10]. Organisations including the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) are already promoting this agenda to their members, producing guidelines and supporting their implementation to increase the quality of asthma care throughout Europe.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Map of stakeholders in the asthma domain. CRO: contract research organisation; NGO: non-governmental organisation; HVAC: heating ventilation and air-conditioning; ICT: information and communication technology.

Call to action: a demand-driven research agenda

Europe is ideally placed to capitalise on the research potential of the EARIP agenda. Radical improvements in asthma outcomes and the related impact on the overall European economy are only achievable through a coordinated and concerted approach at international level. Our calls/recommendations include: 1) A strategic research framework for asthma (a demand-driven agenda developed in consultation with stakeholders, to ensure public and private resources are focused on research priority areas); 2) A commitment to addressing asthma at the European level; 3) Adoption and dissemination of the research priorities, roadmap and recommendations established by EARIP; 4) An Innovative Medicines Initiative (IMI) project addressing the full spectrum and various subgroups of asthma.

Existing multi-stakeholder hubs and consortia with proven innovative capacity can act as catalysts for expansion. A successful example is the Global Allergy and Asthma European Network (GA2LEN), a flagship Sixth Framework Programme (FP6) Network of Excellence, which remains sustainable and has served as an innovation forum for a large number of academic, civil society and industrial partners [11]. Following a number of workshops with various stakeholders at the European Respiratory Society International Congresses in 2014 and 2015, and the European Academy of Allergy and Clinical Immunology Congress in 2015, EARIP proposes that, if there is commitment that enables proper action to be taken, it would be possible to reduce the asthma burden in Europe by 40% within the next 10 years. A number of indices, such as hospitalisations, deaths, prevalence and cost can be utilised as further milestones reflecting the societal impact. To achieve this, research results should be rapidly incorporated into commercial applications and impactful public health programmes.

Disclosures

Supplementary Material

R. Djukanovic ERJ-02294-0216_Djukanovic

C. Akdis ERJ-02294-2016_Akdis

A. Androutsopoulou ERJ-02294-2016_Androutsopoulou

J. Edwards ERJ-02294-2016_Edwards

S. L. Johnston ERJ-02294-2016_Johnston

T. R. Martin ERJ-02294-2016_Martin

D. Myles ERJ-02294-2016_Myles

S. Palkonen ERJ-02294-2016_Palkonen

N. G. Papadopoulos ERJ-02294-2016_Papadopoulos

P.Powell ERJ-02294-2016_Powell

J. Riley ERJ-02294-2016_Riley

Footnotes

  • Support statement: Support was provided by the European Commission Seventh Framework Programme (GA: 602077). Funding information for this article has been deposited with the Crossref Funder Registry

  • Conflict of interest: Pippa Powell is an employee of the European Lung Foundation (ELF). Further disclosures can be found alongside this article at erj.ersjournals.com

  • Received November 22, 2016.
  • Accepted April 11, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    Global Initiative for Asthma (GINA) Program. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–478. http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2004.00526.x/epdf Date last accessed: April 13 2017.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Childhood asthma. In: Gibson J, Loddenkemper R, Sibille Y, Lundbäck B, eds. European Lung White Book. 2nd Edn. Sheffield, European Respiratory Society, 2013; pp. 126–137. www.erswhitebook.org/chapters/childhood-asthma/ Date last accessed: April 13 2017.
  3. ↵
    Global Asthma Network. The global asthma report 2014. Global Asthma Network, Auckland, 2014. www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf Date last accessed: April 13 2017.
  4. ↵
    1. Williams AE,
    2. Lloyd AC,
    3. Watson L, et al.
    Cost of scheduled and unscheduled asthma management in seven European Union countries. Eur Respir Rev 2006; 15: 4–9.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Decramer M,
    2. Sibille Y
    , eds. European Respiratory Roadmap. Sheffield, European Respiratory Society, 2011.
  6. ↵
    1. Masefield S
    . European Asthma Research and Innovation Partnership (EARIP). In: Powell P, ed. The state of play in European asthma research 2015. London, EARIP Consortium, 2015. https://earip.eu/wp-content/uploads/EARIP%20D6.1%20European%20'State%20of%20Play'%20document%20for%20asthma%20research.pdf Date last accessed: April 13 2017.
  7. ↵
    Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED). www.europeanlung.org/en/projects-and-research/projects/u-biopred/ Date last accessed: April 13 2017.
  8. ↵
    European Commission. Commission staff working document: use of ‘-omics’ technologies in the development of personalised medicine. Brussels, European Commission, 2013. https://ec.europa.eu/research/health/pdf/2013-10_personalised_medicine_en.pdf#view=fit&pagemode=none Date last accessed: April 13 2017.
  9. ↵
    1. Masefield SC,
    2. Powell P,
    3. Kennington EJ, et al.
    Driving investment in asthma research in Europe: priorities to prevent, cure and manage asthma more effectively. Am J Respir Crit Care Med 2016; 193: A2668.
    OpenUrl
  10. ↵
    1. Masefield S,
    2. Edwards J,
    3. Hansen K, et al.
    The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). Eur Respir J 2017; 49: 1602295.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    The Global Allergy and Asthma European Network (GA²LEN). www.ga2len.net Date last accessed: April 13 2017.
PreviousNext
Back to top
View this article with LENS
Vol 49 Issue 5 Table of Contents
European Respiratory Journal: 49 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Asthma research in Europe: a transformative agenda for innovation and competitiveness
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Asthma research in Europe: a transformative agenda for innovation and competitiveness
Nikolaos G. Papadopoulos, Aggeliki Androutsopoulou, Cezmi Akdis, Sven-Erik Dahlén, Ratko Djukanovic, Jessica Edwards, Luis Garcia-Marcos, Sebastian L. Johnston, Maciek Kupczyk, Thomas R. Martin, David Myles, Susanna Palkonen, Pippa Powell, John Riley, Samantha Walker
European Respiratory Journal May 2017, 49 (5) 1602294; DOI: 10.1183/13993003.02294-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Asthma research in Europe: a transformative agenda for innovation and competitiveness
Nikolaos G. Papadopoulos, Aggeliki Androutsopoulou, Cezmi Akdis, Sven-Erik Dahlén, Ratko Djukanovic, Jessica Edwards, Luis Garcia-Marcos, Sebastian L. Johnston, Maciek Kupczyk, Thomas R. Martin, David Myles, Susanna Palkonen, Pippa Powell, John Riley, Samantha Walker
European Respiratory Journal May 2017, 49 (5) 1602294; DOI: 10.1183/13993003.02294-2016
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Europe at the forefront of a medical research revolution: an opportunity for change
    • Asthma: an unmet need and an economic opportunity
    • The European Asthma Research and Innovation Partnership: a transformative agenda for research and innovation
    • Call to action: a demand-driven research agenda
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Editorials

  • Addressing the effect of ancestry on lung volume
  • Consensus statement on quality standards for managing children with bronchiectasis
  • Bronchodilators in bronchiectasis: there is light but it is still too dim
Show more Editorials

European lung corner

  • H2020 funding for respiratory research
  • Plain packaging of tobacco products in the EU
  • Standard operating procedures for tuberculosis care
Show more European lung corner

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society